Bone marrow microenvironment: The guardian of leukemia stem cells

doi:10.4252/wjsc.v11.i8.476

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10756)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

752

WORD

289

HTML

6470

Figures (1-4)

383

Tables (1-4)

219

Sum=8113

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

346

Download

618

Sum=964

Publishing Process of This Article

Item

Count

Browse

764

Download

915

Sum=1679

Aug 26, 2019 (publication date) through Jul 3, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Aug 26, 2019; 11(8): 476-490
Published online Aug 26, 2019. doi: 10.4252/wjsc.v11.i8.476

Table 4 A draft of compounds under clinical trial in leukemic stem cell bone marrow microenvironment target therapy

Disease	Target	Compound	Clinical trial ID
CML	CXCR4	BL-8040	NCT02115672
CML	IL-1RAP	CAR-LMC	NCT02842320
CML	JAK-inhibitor	Ruxolitinib	NCT01702064, NCT03654768, NCT01751425, NCT03610971
AML	CXCR4	Plerixafor (AMD3100)	NCT01455025
AML	Hypoxia	TH-302	NCT01149915
AML	VEGF	Aflibercept	NCT00601991
AML	VLA-4	AS101	NCT01010373
AML	Ang-1/2	Trebananib (AMG 386)	NCT01555268
AML	CD47	SRF231, TTI-621, CC90002, Hu5F9-G4	NCT03512340, NCT02663518, NCT02367196, NCT02678338, NCT03248479
AML	Notch	LY3039478, MK0752	NCT01695005, NCT00100152
AML	XIAP	AEG35156	NCT00363974
AML	BH3	ABT-199	NCT01994837
AML	Pan FGFR	LY274455	NCT01212107

CML: Chronic myeloid leukemia; AML: Acute myeloid leukemia; CXCR4: C-X-C chemokine receptor type 4; IL-1RAP: Interleukin-1 receptor accessory protein; JAK: Janus kinase; VEGF: Vascular endothelial growth factor; VLA-4: Very late antigen-4; Ang-1/2: angiopoietin-1/2; XIAP: X-Linked inhibitor of apoptosis; FGFR: Fibroblast growth factor receptor.

Citation: Houshmand M, Blanco TM, Circosta P, Yazdi N, Kazemi A, Saglio G, Zarif MN. Bone marrow microenvironment: The guardian of leukemia stem cells. World J Stem Cells 2019; 11(8): 476-490
URL: https://www.wjgnet.com/1948-0210/full/v11/i8/476.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i8.476